Examining Ibrutinib Plus Venetoclax as a Treatment Option for CLL

April 16, 2019

William G. Wierda, MD, PhD, discusses data surrounding the use of ibrutinib in combination with venetoclax as a treatment option for patients with newly diagnosed CLL as well as relapsed CLL.

William G. Wierda, MD, PhD, professor in the department of leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses data surrounding the use of ibrutinib (Imbruvica) in combination with venetoclax (Venclexta) as a treatment option for patients with newly diagnosed chronic lymphocytic leukemia (CLL) as well as relapsed CLL.

At the 2018 ASH Annual Meeting, several trials reported results from this combination in CLL. MD Anderson has a clinical trial including 2 cohorts of patients: a relapsed cohort and a frontline cohort. Wierda also says the CLARITY trial, reported by the UK Group, is looking at this combination in relapsed patients, while the Ohio State Comprehensive Cancer Center has a trial investigating this combination plus an anti-CD20 antibody.